Shire reports first sales after neuroscience, rare disease split

In its 1Q18 earnings, Shire plc (LSE:SHP; NASDAQ:SHPG) released its first figures since splitting its neuroscience and rare disease businesses into two divisions (see BioCentury Extra, Jan. 9).

For the quarter, Shire's rare disease division generated revenues of $2.7 billion, a 10% increase from the same period in 2017. Total revenues from its neuroscience division fell 2% to $918 million. Excluding sales of ulcerative colitis drug Lialda mesalamine, the neuroscience division reported a 12% increase in total revenues...